We are live on
!
Find out more
CIM
Contravisory Investment Management Portfolio holdings
AUM
$566M
1-Year Est. Return
42.93%
This Fund
S&P 500
This Quarter
Est. Return
-8.73%
1 Year Est. Return
+42.93%
3 Year Est. Return
+129.34%
5 Year Est. Return
+198.47%
10 Year Est. Return
+603.03%
AUM
$308M
AUM Growth
-$44.2M
(-13%)
Cap. Flow
-$4.71M
Cap. Flow
% of AUM
-1.53%
Top 10 Holdings %
Top 10 Hldgs %
25.53%
Holding
393
New
63
Increased
64
Reduced
89
Closed
70
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$6.58M |
| 2 |
Conagra Brands
CAG
|
+$6.41M |
| 3 |
General Mills
GIS
|
+$6.28M |
| 4 |
Becton Dickinson
BDX
|
+$6.25M |
| 5 |
Procter & Gamble
PG
|
+$6.16M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Accenture
ACN
|
+$8.69M |
| 2 |
Zebra Technologies
ZBRA
|
+$8.06M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$7.68M |
| 4 |
Moody's
MCO
|
+$7.1M |
| 5 |
Zoetis
ZTS
|
+$6.57M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.62% |
| 2 | Financials | 14.7% |
| 3 | Energy | 12.88% |
| 4 | Consumer Staples | 11.59% |
| 5 | Industrials | 9.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
McKesson
MCK
$98.5B
| $11M | 3.56% |
33,659
-1,384
| -4% | -$443K |
|
2
UnitedHealth
UNH
$382B
| $8.98M | 2.91% |
17,475
-555
| -3% | -$279K |
|
3
Halliburton
HAL
$27.9B
| $8.33M | 2.7% |
265,753
-16,489
| -6% | -$615K |
|
4
Microsoft
MSFT
$2.84T
| $7.87M | 2.55% |
30,625
-2,650
| -8% | -$719K |
|
5
Marathon Petroleum
MPC
$90.3B
| $7.7M | 2.5% |
93,645
-2,402
| -3% | -$225K |
|
6
Eli Lilly
LLY
$1.07T
| $7.37M | 2.39% |
22,729
-217
| -0.9% | -$65.1K |
|
7
SLB Ltd
SLB
$77.8B
| $7.11M | 2.31% |
198,736
-3,121
| -2% | -$130K |
|
|
CMA
8
DELISTED
Comerica
CMA
| $6.82M | 2.21% |
92,956
-259
| -0.3% | -$20.9K |
|
|
9
Merck
MRK
$324B
| $6.79M | 2.2% |
74,448
+74,188
| +28,534% | +$6.58M |
|
|
10
General Mills
GIS
$19.2B
| $6.77M | 2.2% |
+89,698
| New | +$6.28M |
|
|
11
Conagra Brands
CAG
$7.07B
| $6.44M | 2.09% |
+188,092
| New | +$6.41M |
|
12
Baker Hughes
BKR
$56.8B
| $6.42M | 2.08% |
222,365
-1,981
| -0.9% | -$67K |
|
13
Mettler-Toledo International
MTD
$26.8B
| $6.42M | 2.08% |
5,584
-76
| -1% | -$95.5K |
|
14
Westlake Corp
WLK
$9.46B
| $6.35M | 2.06% |
64,781
-835
| -1% | -$102K |
|
15
Entergy
ETR
$54.1B
| $6.34M | 2.06% |
112,538
+7,016
| +7% | +$413K |
|
16
RTX Corp
RTX
$287B
| $6.34M | 2.06% |
65,944
-121
| -0.2% | -$11.6K |
|
17
Elevance Health
ELV
$81.9B
| $6.23M | 2.02% |
12,910
-56
| -0.4% | -$27.7K |
|
|
18
Procter & Gamble
PG
$343B
| $6.1M | 1.98% |
42,435
+41,002
| +2,861% | +$6.16M |
|
19
Republic Services
RSG
$66.7B
| $6.08M | 1.97% |
+46,427
| New | +$6.1M |
|
20
Equity Residential
EQR
$25.4B
| $6.07M | 1.97% |
84,026
-580
| -0.7% | -$46K |
|
|
21
Becton Dickinson
BDX
$43.1B
| $6.07M | 1.97% |
+24,600
| New | +$6.25M |
|
22
Travelers Companies
TRV
$80.8B
| $6.05M | 1.96% |
35,758
-300
| -0.8% | -$52.1K |
|
23
Southern Company
SO
$110B
| $5.98M | 1.94% |
+83,819
| New | +$6.15M |
|
24
Mondelez International
MDLZ
$77.7B
| $5.91M | 1.92% |
+95,182
| New | +$6.01M |
|
25
Ulta Beauty
ULTA
$20.4B
| $5.84M | 1.89% |
15,143
+956
| +7% | +$380K |
|
Similar funds
FG
SAM
BCMLT
KJWM
PAM
PEP
OC
LC
Contravisory Investment Management's Q2 2022 Portfolio in Review
As of Q2 2022, Contravisory Investment Management held 393 positions worth $308M, down 13% from $352M the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Contravisory Investment Management's Q2 2022 filing shows 63 new, 64 increased, 89 reduced and 70 closed positions. Its largest new stake was Conagra Brands: 188,092 shares worth $6.44M. The largest sale was Accenture, an estimated $8.69M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 15% a quarter earlier, followed by Financials and Energy.
- Contravisory Investment Management's largest Q2 2022 buy was Conagra Brands: 188,092 shares worth $6.44M.
- Contravisory Investment Management added most to Merck in Q2 2022, an estimated $6.58M increase.
- Contravisory Investment Management's biggest Q2 2022 reduction was Accenture, cutting an estimated $8.69M.
- Contravisory Investment Management fully exited Zebra Technologies in Q2 2022, selling an estimated $8.06M.
- Contravisory Investment Management's ten largest holdings make up 26% of its $308M portfolio in Q2 2022.
- Contravisory Investment Management opened 63 new positions and closed 70 in Q2 2022.
- Contravisory Investment Management's portfolio value fell 13% quarter-over-quarter to $308M.
Based on Contravisory Investment Management's 13F filing for Q2 2022, filed 13 Jul 2022.